SyneuRx™ International announced it has completed enrollment for its Phase II clinical trial evaluating the efficacy and safety of SNB01 (‘Pentarlandir’), a novel COVID-19 oral antiviral candidate.
[SyneuRx™ International]
Sorry, but the selected Zotpress account can't be found.